Produção Nacional
Revisado por pares
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial
2024; Elsevier BV; Volume: 68; Linguagem: Inglês
10.1016/j.eclinm.2023.102383
ISSN2589-5370
AutoresSuzana Margareth Lobo, Gaëtan Plantefève, Girish B. Nair, Adilson Joaquim Westheimer Cavalcante, Nara Franzin de Moraes, Estêvão Portela Nunes, Otis Barnum, Claudio Stadnik, Maria Patelli Juliani Souza Lima, Muriel Lins, Ludhmila Abrahão Hajjar, Christopher A. Lipinski, Shaheen Islam, Fabiano Ramos, Tiago Simon, Jean‐Benoît Martinot, Thomas Guimard, Arnaud Desclaux, Bertrand Lioger, Fernando Carvalho Neuenschwander, Bruno DeSouza Paolino, Alpesh Amin, Samuel Amil Acosta, Daniel F. Dilling, Edgardo Cartagena, Brian D. Snyder, Edouard Devaud, Ana Karolina Barreto Berselli Marinho, Suzana Érico Tanni, Patricia Medeiros Milhomem Beato, S. De Wit, V. Saravana Selvan, Jeffrey A. Gray, Ricardo Fernández, Valérie Pourcher, Lee Maddox, Richard Kay, Anait Azbekyan, Mounia Chabane, Cendrine Tourette, Luis Everton Esmeraldino, Pierre J. Dilda, René Lafont, Jean Mariani, Serge Camelo, Sandrine Rabut, Samuel Agus, Stanislas Veillet, Waly Dioh, Rob van Maanen, Capucine Morélot‐Panzini,
Tópico(s)Thermal Regulation in Medicine
ResumoBackgroundSARS-CoV-2 binding to ACE2 is potentially associated with severe pneumonia due to COVID-19. The aim of the study was to test whether Mas-receptor activation by 20-hydroxyecdysone (BIO101) could restore the Renin-Angiotensin System equilibrium and limit the frequency of respiratory failure and mortality in adults hospitalized with severe COVID-19.MethodsDouble-blind, randomized, placebo-controlled phase 2/3 trial. Randomization: 1:1 oral BIO101 (350 mg BID) or placebo, up to 28 days or until an endpoint was reached. Primary endpoint: mortality or respiratory failure requiring high-flow oxygen, mechanical ventilation, or extra-corporeal membrane oxygenation. Key secondary endpoint: hospital discharge following recovery (ClinicalTrials.gov Number, NCT04472728).FindingsDue to low recruitment the planned sample size of 310 was not reached and 238 patients were randomized between August 26, 2020 and March 8, 2022. In the modified ITT population (233 patients; 126 BIO101 and 107 placebo), respiratory failure or early death by day 28 was 11.4% lower in the BIO101 (13.5%) than in the placebo (24.3%) group, (p = 0.0426). At day 28, proportions of patients discharged following recovery were 80.1%, and 70.9% in the BIO101 and placebo group respectively, (adjusted difference 11.0%, 95% CI [−0.4%, 22.4%], p = 0.0586). Hazard Ratio for time to death over 90 days: 0.554 (95% CI [0.285, 1.077]), a 44.6% mortality reduction in the BIO101 group (not statistically significant). Treatment emergent adverse events of respiratory failure were more frequent in the placebo group.InterpretationBIO101 significantly reduced the risk of death or respiratory failure supporting its use in adults hospitalized with severe respiratory symptoms due to COVID-19.FundingBiophytis.
Referência(s)